ArticleBMC cancer2025
Does severe mucositis impair oncological outcome in head and neck cancer patients? A pooled analysis of two prospective studies with long-term follow-up.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Emerging Role of Olfactory Receptors: From Genomics to Precision Medicine.Molecular diagnosis & therapy · 2026Review
- Increased acid sphingomyelinase levels in saliva as oral mucositis severity predictors.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOral mucositis (OM) is a frequently reported radiotherapy (RT)-induced acute toxicity in head and neck (H&N) cancer patients. Severe OM may be a dose-limiting condition, which can affect oncological outcomes. Therefore, we conducted a pooled analysis of two prospective studies with long-term follow-up to evaluate the impact of grade ≥3 OM on outcomes.
methodsThis pooled analysis included 253 H&N cancer patients who received primary definitive or adjuvant chemoradiotherapy at the University of Freiburg Medical Center. Kaplan-Meier analyses with log-rank tests stratified for the presence of grade 3 OM were performed for overall survival (OS), local recurrence-free survival (LRFS), and distant-metastasis free survival (DMFS). Univariate Cox proportional hazards regression was performed to identify prognostic factors for OS, LRFS, and DMFS.
resultsThe majority of participants had locally advanced disease: UICC stage IVA in 157 (62.1%) and IVB in 31 (12.3%). During treatment, 168 (66.4%) participants developed grade 3 OM. After a median follow-up of 73.6 months, the median OS was 64.6 months (95% CI, 47.6-83.7), and the median LRFS and DMFS had not yet been reached. Advanced disease stages had a significant impact on OS as follows: UICC IVb vs. I, HR 4.62 (95%-CI: 1.364-5.637, SE 0.6, p = 0.014) and UICC IVc vs. I, HR 9.01 (95%-CI: 1.500-54.1643, SE = 0.9, p = 0.016). Previous surgery also has a significant impact on OS with an HR 0.65 (95% CI: 0.440-0.948, SE 0.2, p = 0.026). RT duration also showed a significant impact on OS with HR 1.03 (95% CI: 1.002-1.067, SE = 0, p = 0.040). For LRFS, prior surgery had a significant impact with an HR of 0.46 (95% CI: 0.247-0.857, SE 0.3, p = 0.014). Furthermore, the cumulative RT dose had a measurable impact on LRFS with HR 1.10 (95% CI: 1.022-1.189, SE = 0.03, p = 0.012). Smoker status showed a significant effect on DMFS with an HR 3.29 (95% CI: 1.090-9.872, SE 0.561, p = 0.034). The presence of grade 3 OM has no significant impact on LRFS, OS, or DMFS.
conclusionsSevere acute grade 3 OM shows no long-term impact on oncological endpoints. Validation in larger multicenter cohorts is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.